Vizirgianakis Files 13D for Apyx Medical Corp

TL;DR

**VIZIRGIANAKIS FILES 13D ON APYX MEDICAL CORP (APYX)**

AI Summary

Stavros G. Vizirgianakis has filed a Schedule 13D for Apyx Medical Corporation, indicating a change in beneficial ownership. The filing was made on April 1, 2024, with the date of the event requiring the filing being March 25, 2024. Vizirgianakis is listed with an address in Williamstown North, Victoria, Australia.

Why It Matters

This filing signals a potential shift in control or significant influence over Apyx Medical Corporation by Stavros G. Vizirgianakis, which could impact the company's strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — Schedule 13D filings often precede significant corporate actions or changes in control, introducing uncertainty and potential volatility.

Key Numbers

• 0000719135 — Central Index Key (Apyx Medical Corporation's identifier)
• 0001559834 — Central Index Key (Stavros G. Vizirgianakis's identifier)
• 20240401 — Filing Date (Date the SC 13D was filed)
• 20240325 — Event Date (Date of event requiring filing)

Key Players & Entities

• Apyx Medical Corporation (company) — Subject Company
• Stavros G. Vizirgianakis (person) — Filing Person
• Amy E. Culbert, Esq. (person) — Authorized Contact
• Fox Rothschild LLP (company) — Legal Counsel

FAQ

Key Financial Figures

• $0.001 — ration (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securitie
• $1.25 — ce of these purchases was approximately $1.25 per share and the source and amount of
• $2,182,660 — n the aggregate amount of approximately $2,182,660. Item 4. Purpose of Transaction. Mr

Filing Documents

• ef20025615_sc13d.htm (SC 13D) — 50KB
• 0001140361-24-016912.txt ( ) — 52KB

From the Filing

SC 13D 1 ef20025615_sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ___)* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) Stavros G. Vizirgianakis c/o Amy E. Culbert, Esq. Fox Rothschild LLP 33 South Sixth Street, Suite 3600 Minneapolis, MN 55402 (612) 607-7287 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) March 25, 2024 (Date of Event Which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes) CUSIP NO. 03837C106 SCHEDULE 13D 1 NAMES OF REPORTING PERSONS Stavros G. Vizirgianakis 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) (b) 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) PF 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E) 6 CITIZENSHIP OR PLACE OF ORGANIZATION Greece and South Africa NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 7 SOLE VOTING POWER 1,746,191 8 SHARED VOTING POWER 0 9 SOLE DISPOSITIVE POWER 1,746,191 10 SHARED DISPOSITIVE POWER 0 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,746,191 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.04% 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN Page 2 of 6 Item 1. Security and Issuer. This Statement on Schedule 13D (this "Schedule 13D") relates to the common stock, par value $0.001 per share, of Apyx Medical Corporation, a Delaware corporation ("APYX"). The address of the principal executive offices of APYX is 5115 Ulmerton Road, Clearwater, Florida 33760. Item 2. Identity and Background. (a) The name of the reporting person is Stavros G. Vizirgianakis. (b) Mr. Vizirgianakis's address is 99 Boulevard du Jardin, Exotique, Monaco, 98000. (c) Mr. Vizirgianakis's principal occupation is private medical technology and biotechnology investor and advisor. (d) During the last five years, Mr. Vizirgianakis has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the last five years, Mr. Vizirgianakis was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was not or is not subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Mr. Vizirgianakis is a citizen of Greece and a citizen of South Africa. Item 3. Source and Amount of Funds or Other Consideration. On March 22 and 25, 2024, Mr. Vizirgianakis purchased an aggregate of 1,746,191 shares of APYX common stock in open market purchase transactions. The weighted average purchase price of these purchases was approximately $1.25 per share and the source and amount of funds used by Mr. Vizirgianakis to acquire these shares were personal funds in the aggregate amount of approximately $2,182,660. Item 4. Purpose of Transaction. Mr. Vizirgianakis acquired beneficial ownership of the shares of APYX common stock reported herein as part of his personal investment activities and because he believes that the recent trading prices of APYX common stock do not adequately reflect the potential value of APYX's underlying business and assets. Mr. Vizirgianakis desires to engage with management and the board of directors of APYX to discuss the numerous issues facing APYX today and in the near future and would like to work with management and the board of directors of APYX to conduct a strategic review of all commercial activities and to gain deeper insight into the financial and operational challenges that lie ahead so that any necessary changes and meaningful actions can be implemented to address shareholder concerns, restore confidence and drive value creation. Page 3 of 6 With respect to his investmen

View Full Filing

View this SC 13D filing on SEC EDGAR